Related Experiment Videos
Dehydrophenylalanine derivatives as VLA-4 integrin antagonists
John R Porter1, Sarah C Archibald, Julien A Brown
1Department of Medicinal Chemistry, Celltech R&D Ltd, 216 Bath Road, Slough SL1 4EN, UK. john.porter@celltechgroup.com
Bioorganic & Medicinal Chemistry Letters
|March 6, 2003
Summary
Researchers developed potent VLA-4 antagonists from dehydrophenylalanine derivatives. Configurationally constrained molecules led to a novel class of benzodiazepine VLA-4 antagonists with improved properties.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- Integrin alpha-4 (VLA-4) is a key target for inflammatory diseases.
- Previous VLA-4 antagonists faced challenges with rapid clearance.
- Dehydrophenylalanine derivatives offer a scaffold for constrained antagonists.
Purpose of the Study:
- To design and synthesize novel VLA-4 antagonists.
- To investigate the structure-activity relationship of dehydrophenylalanine derivatives.
- To develop VLA-4 antagonists with improved pharmacokinetic profiles.
Main Methods:
- Synthesis of Z and E isomers of dehydrophenylalanine derivatives.
- In vitro evaluation of VLA-4 antagonist activity.
- Pharmacokinetic studies assessing biliary clearance rates.
Main Results:
- Z isomers demonstrated potent VLA-4 antagonism but rapid biliary clearance.
- E isomers exhibited weaker activity but slower clearance.
- These findings guided the design of novel benzodiazepine-based VLA-4 antagonists.
Conclusions:
- Configurational constraint in dehydrophenylalanine derivatives influences VLA-4 antagonist potency and pharmacokinetics.
- Novel benzodiazepine derivatives represent a promising new class of VLA-4 antagonists.
- Further optimization may yield improved therapeutics for VLA-4 mediated conditions.